The market reacted positively, up 7.2%, reflecting investor approval of above-guidance organic growth, record sales, and margin stability across all segments.
- Third quarter sales reached a record $818 million, up 10% year-over-year, driven by 12% organic growth across all three business segments.
- Adjusted EPS of $3.25 was a record and $0.10 above the high end of guidance, representing a 19% increase from the prior year.
- EBITDA was $262 million, a company record, with a margin of 32% of sales, maintaining profitability despite inflationary pressures.
- Order backlog rose 35% year-over-year, supported by strength in Advanced Technology and Medical segments, indicating sustained demand momentum.
- Free cash flow was robust at $237 million, supporting balance sheet flexibility for future strategic investments.
Community Discussion